WuXi Biologics (Cayman)'s Total Assets for the quarter that ended in Dec. 2023 was €7,266 Mil.
Warning Sign:
If a company builds assets at 53.6% a year, faster than its revenue growth rate of 45.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, WuXi Biologics (Cayman)'s average Total Assets Growth Rate was 8.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 26.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 53.60% per year.
During the past 10 years, WuXi Biologics (Cayman)'s highest 3-Year average Total Assets Growth Rate was 94.40%. The lowest was 26.90%. And the median was 61.20%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
WuXi Biologics (Cayman)'s Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (FRA:1FW2) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
WuXi Biologics (Cayman)'s Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
WuXi Biologics (Cayman) Total Assets Related Terms
Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
WuXi Biologics (Cayman) (FRA:1FW2) Business Description
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:1FW2 has been successfully added to your 